SynBiotic SE risk profile
34 Normal where most of the sector sits
Measured 1 September 2026 from SBX's filed statements. Recomputed nightly.
34 (Normal), driven by Leverage and coverage at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 80 | Acute | Stable | Drawdown from the 52-week high — 82.1% |
| Operating pressure | 1 | Contained | Easing | Input-cost exposure — 0.02 |
| Cash conversion | 91 | Acute | Easing | Capital spending against operating cash — -0.44x |
| Leverage and coverage | 100 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 4 | Contained | Stable | Revenue-growth gap against peers — +56.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.